Intellectual Property

InterveXion holds the exclusive rights to seven issued US patents (6,669,937; 7,202,348; 7,632,929; 7,858,756, 8,299,222, 8,853,146, 9,023,353) and multiple pending US and international patent applications that cover IXT-m200 and/or IXT-v100.  We anticipate that between our patent rights and statutory biologic marketing exclusivity periods, our products will carry a long post-launch exclusivity period if development is successful.